RESUMO
OBJECTIVES: CT-guided biopsy of indeterminate lung lesions sometimes provides insufficient histological results due to tumor necrosis. Functional and metabolic methods such as DWI-MR and PET-CT may help by directing sample collection to a lesion area of greater biological representativeness. The objective is to evaluate the histopathological results based on findings on ADC and SUV levels in lung lesions suspected for primary cancer. METHODS: Tissue samples were evaluated after undergoing biopsies guided by either DWI-MR or PET-CT findings. In each patient, sample collection from two lesion areas was guided by local ADC and SUV. Values were used to define areas of low vs. high suspicion for cancer. RESULTS: Patients who underwent DWI-MR had median lesion size of 78.0 mm. Areas of higher suspicion (HSA) had a median ADC of 1.1 × 10-3 mm2/s, while areas of lower suspicion (LSA) had median ADC of 1.8 × 10-3 mm2/s (p = 0.0001). All HSA samples and 71.43% of LSA samples were positive for cancer (p = 0.0184). Patients who performed PET-CT had median lesion size of 61.0 mm. Median SUV was 7.1 for HSA and 3.9 for LSA (p = 0.0002). Positivity for cancer was observed in 76.9% of samples for both HSA and LSA (p = 0.0522). CONCLUSION: Use of DWI-MR and PET-CT showed that tumors are functional and metabolically heterogeneous and that this heterogeneity has implications for histopathological diagnosis. KEY POINTS: ⢠Lung cancer is heterogeneous regarding functional and metabolic imaging. ⢠Tumor heterogeneity may have implications in histopathological diagnosis. ⢠Intralesional lower levels of ADC target highly suspected areas with a significant improvement in lung cancer diagnosis.
Assuntos
Imagem de Difusão por Ressonância Magnética/métodos , Biópsia Guiada por Imagem/métodos , Neoplasias Pulmonares/diagnóstico , Pulmão/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Adulto , Idoso , Estudos Transversais , Feminino , Fluordesoxiglucose F18/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Compostos Radiofarmacêuticos/farmacologiaRESUMO
Quantification of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) can be time-consuming. We evaluated the performance of an automatic multifocal segmentation (MFS) method of quantification in patients with different stages of Hodgkin lymphoma, using the multiple VOI (MV) method as reference. Methods: This prospective bicentric study included 50 patients with Hodgkin lymphoma who underwent staging 18F-FGD PET/CT. The examinations were centrally reviewed and processed with commercial MFS software to obtain MTV and TLG using 2 fixed relative thresholds (40% and 20% of SUVmax) for each lesion. All PET/CT scans were processed using the MV and MFS methods. Interclass correlation coefficients and Bland-Altman plots were used for statistical analysis. Repeated calculations of MTV and TLG values by 2 observers with different degrees of PET/CT imaging experience were used to ascertain interobserver agreement on the MFS method. Results: The means and SDs obtained for the MTV with MV and MFS were, respectively, 736 ± 856 mL and 660 ± 699 mL for the 20% threshold and 313 ± 359 mL and 372 ± 434 mL for the 40% threshold. The time spent calculating the MTV was much shorter with the MFS method than with the MV method (median time, 11.6 min [range, 1-30 min] and 64.4 min [range, 1-240 min], respectively), especially in patients with advanced disease. Time spent was similar in patients with localized disease. There were no statistical differences between the MFS values obtained by the 2 different observers. Conclusion: MTV and TLG calculations using MFS are reproducible, generate similar results to those obtained with MV, and are much less timing-consuming. Main differences between the 2 methods were related to difficulties in avoiding overlay of VOIs in the MV technique. MV and MFS perform equally well in patients with a small number of lesions.
Assuntos
Fluordesoxiglucose F18/farmacologia , Doença de Hodgkin/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Compostos Radiofarmacêuticos/farmacologia , Carga Tumoral/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Fluordesoxiglucose F18/química , Glicólise , Humanos , Masculino , Pessoa de Meia-Idade , Imagem Multimodal , Estadiamento de Neoplasias , Prognóstico , Estudos Prospectivos , Compostos Radiofarmacêuticos/química , Estudos Retrospectivos , Fatores de TempoRESUMO
Guidelines recommend true whole-body 18F-FDG PET/CT scans from vertex to toes in pediatric lymphoma patients, although this suggestion has not been validated in large clinical trials. The objective of the study was to evaluate the incidence and clinical impact of lesions outside the "eyes to thighs" regular field of view (R-FOV) in 18F-FDG PET/CT staging (sPET) and interim (iPET) scans in pediatric lymphoma patients. Methods: True whole-body sPET and iPET scans were prospectively obtained in pediatric lymphoma patients (11 worldwide centers). Expert panel central review of sPET and iPET scans were evaluated for lymphoma lesions outside the R-FOV and clinical relevance of these findings. Results: A total of 610 scans were obtained in 305 patients. The sPET scans did not show lesions outside the R-FOV in 91.8% of the patients, whereas in 8.2% patients the sPET scans demonstrated lesions also outside the R-FOV (soft tissue, bone, bone marrow, and skin); however, the presence of these lesions did not change the clinical stage of any patient and did not affect treatment decision. Among the 305 iPET scans, there were no new positive 18F-FDG-avid lesions outside the R-FOV, when compared with their paired sPET scans. A single lesion outside the R-FOV on iPET occurred in 1 patient (0.3%), with the primary lesion diagnosed in the femur on sPET that persisted on iPET. Conclusion: The identification of additional lesions outside the R-FOV (eyes to thighs) using 18F-FDG PET/CT has no impact in the definition of the clinical stage of disease and minimal impact in the treatment definition of patients with pediatric lymphoma. As so, R-FOV for both sPET and iPET scans could be performed.
Assuntos
Fluordesoxiglucose F18/farmacologia , Linfoma/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Adolescente , Criança , Pré-Escolar , Feminino , Doença de Hodgkin/diagnóstico por imagem , Humanos , Lactente , Linfoma não Hodgkin/diagnóstico por imagem , Masculino , Estudos Prospectivos , Reprodutibilidade dos Testes , Imagem Corporal Total/métodosRESUMO
Chylothorax, the abnormal accumulation of lymphatic fluid within the pleural space, is an infrequent complication of tumours affecting the mediastinum. The development of chylothorax is extraordinary in association with prostate cancer, although it has been described before. Adequate treatment of malignant chylothorax comprises both a conservative approach, including dietary and hormonal manipulations, and mechanic intercostal drainage that have been demonstrated to be effective in the management of chylothorax of malignant origin. Radiation therapy has been used for the treatment of neoplasic chylothorax but with inconsistent results. We present a new case of chylothorax associated to prostate adenocarcinoma and review the existing evidence for its treatment.
Assuntos
Adenocarcinoma/patologia , Quilotórax/complicações , Quilotórax/diagnóstico , Mediastino/patologia , Neoplasias da Próstata/complicações , Neoplasias da Próstata/patologia , Biópsia , Evolução Fatal , Fluordesoxiglucose F18/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Tomografia por Emissão de Pósitrons , Radioterapia/métodos , Tomografia Computadorizada por Raios X/métodos , Resultado do TratamentoAssuntos
Angiografia Coronária/métodos , Vasos Coronários/patologia , Fluordesoxiglucose F18/farmacologia , Coração/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Idoso , Aterosclerose/diagnóstico , Aterosclerose/patologia , Humanos , Inflamação , Masculino , Estudos Retrospectivos , FumarRESUMO
INTRODUCTION: The radiochemical 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG), a positron emitter, is taken up preferentially by malignant tumors with high metabolic rates. This concentration of 18F-FDG in the tumor permits diagnosis and staging by positron emission tomography but also may represent a means of targeting radiotherapy. In this study, we determined the effect of a higher dose of 18F-FDG on tumor growth in a mouse model. MATERIALS AND METHODS: The effect of 18F-FDG on the growth and viability of 3 tumor cell lines was determined in vitro. Primary tumor growth and metastasis of B16/BL6 melanoma cells were determined in C57BL/6 mice injected with 5 mCi doses of 18F-FDG (2/3 doses). RESULTS: 18F-FDG was cytostatic for all 3 cell lines at the lowest dose tested. It significantly reduced the growth of primary tumors, by 89% at day 19 postinoculation, and also almost totally inhibited the appearance of lung metastases after intravenous inoculation of the same cells. CONCLUSIONS: 18F-FDG proved to be an effective radiotherapeutic agent in this model. The possible problems associated with the accumulation of this radiochemical at other sites besides the tumor must be addressed.